{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:14:47Z","timestamp":1785334487138,"version":"3.55.0"},"reference-count":53,"publisher":"Microbiology Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:p>\n                  <jats:bold>Introduction.<\/jats:bold> \n                  <jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2765\" xlink:type=\"simple\">Acinetobacter<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> is one of the challenging drug-resistant organisms that can endanger patients' lives if not treated properly.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Aim.<\/jats:bold> This study was designed to investigate the activity of three synergistic antimicrobial combinations against extensive drug-resistant <jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2765\" xlink:type=\"simple\">Acinetobacter<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> isolates; ampicillin\/sulbactam plus amikacin, ampicillin\/sulbactam plus ciprofloxacin, and meropenem plus amikacin.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methodology.<\/jats:bold> Minimum inhibitory concentrations of 100 XDR-<jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2765\" xlink:type=\"simple\">Acinetobacter<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> isolates were determined using the Vitek2 system. The broth micro-dilution method was performed to determine tigecycline MIC. Checkerboard assay was used to evaluate <jats:italic>in vitro<\/jats:italic> activity of the three antibiotic combinations.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results.<\/jats:bold> MIC results by the Vitek 2C system revealed that all <jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2765\" xlink:type=\"simple\">Acinetobacter<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> isolates were resistant to all tested antibiotics except for colistin against which no resistance was reported. As for tigecycline, all isolates were susceptible. Regarding MIC results of each antibiotic, all isolates were resistant to meropenem and ciprofloxacin. While 95\u200a% of isolates were resistant to both ampicillin\/sulbactam and amikacin. The activities of antibiotic combinations by checkerboard assay were as follows: ampicillin\/sulbactam plus amikacin was synergic in 52\u200a%, additive 40\u200a% and indifferent in 8\u200a% of isolates, ampicillin\/sulbactam plus ciprofloxacin was synergic in 40\u200a%, additive 46\u200a% and indifferent in 14\u200a% of isolates, meropenem\/amikacin combination was synergic in 22\u200a%, additive in 49\u200a% of isolates and indifferent in 29\u200a% of isolates. No antagonistic activity was detected against any of the tested antibiotic combinations.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusion.<\/jats:bold> Ampicillin\/sulbactam plus amikacin showed the highest synergistic activity followed by ampicillin\/sulbactam plus ciprofloxacin. This reflects the value of adding aminoglycosides to either of a \u03b2-lactam or quinolone. The tested antibiotic combinations are promising treatment options for XDR-<jats:italic>\n                     <jats:named-content content-type=\"genus\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.2765\" xlink:type=\"simple\">Acinetobacter<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic>.<\/jats:p>","DOI":"10.1099\/jmm.0.001639","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T10:21:20Z","timestamp":1676024480000},"source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of synergistic activity of antibiotic combinations in extensive drug-resistant Acinetobacter species using checkerboard assay"],"prefix":"10.1099","volume":"72","author":[{"given":"Rania M.","family":"Abdel Halim","sequence":"first","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally M.","family":"Saber","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-3857","authenticated-orcid":false,"given":"Noha Alaa Eldin","family":"Fahim","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Faculty of Medicine Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2016.02.009"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.162360"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx322"},{"key":"R4","first-page":"4","article-title":"The frequency of multidrug-resistance and extensively drug resistant Acinetobacter baumannii in west of Iran","volume":"1","author":"Reza","year":"2018","journal-title":"J Clin Microbiol Infect Dis"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2014.19.177.4307"},{"key":"R6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.26719\/2014.20.3.203","article-title":"Phenotypic characterization of Acinetobacter baumannii isolates from intensive care units at a tertiary-care hospital in Egypt","volume":"20","author":"Nageeb","year":"2014","journal-title":"East Mediterr Health J"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2124-9"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2015.01.001"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.3109\/03009734.2014.899279"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.4137\/MBI.S29459"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181e96b91"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05041-11"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003344.pub3"},{"key":"R14","first-page":"28","volume-title":"Johns Hopkins Medicine","year":"2015"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"R16","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-eighth edition (M100)","year":"2018"},{"key":"R17","article-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2015","journal-title":"Version 5.0, valid from 2015-01-01"},{"key":"R18","first-page":"365","volume-title":"Antibiotics in Laboratory Medicine","author":"Pillai","year":"2005"},{"key":"R19","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2015"},{"key":"R20","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2015"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.04.002"},{"key":"R22","first-page":"19","article-title":"Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii","volume":"9","author":"Madadi-Goli","year":"2017","journal-title":"Iran J Microbiol"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1159\/000081033"},{"key":"R24","first-page":"5","volume-title":"Clinical Microbiology Procedures Handbook","author":"Leber","year":"2016"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.1.119"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0208-x"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1408-14"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.09.014"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1590\/S1517-838246420140101"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-015-0043-x"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.3201\/eid0805.020014"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5102-5108.2004"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00858-06"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2014.02.002"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2013.2338"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2009.117"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04379-14"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01011-16"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.masthead.30-1"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-020-00433-7"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S143306"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0300-3"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036649"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.894882"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.919414"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761167"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis270"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00536"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(02)00207-8"},{"key":"R50","first-page":"67","article-title":"Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii","volume":"38","author":"Dinc","year":"2015","journal-title":"New Microbiol"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.190680"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.008"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01231-08"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001639?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T10:21:30Z","timestamp":1676024490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.001639","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}